Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

• Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial
confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients
that benefit from adjuvant clodronate treatment to prevent metastasis.
• Data published in Journal of National Cancer Institute, Cancer Spectrum.
• MAF negative status of patients who were treated with clodronate in the adjuvant setting
was predictive of significantly improved disease-free survival (primary endpoint) and overall
survival (key secondary endpoint).
• Results confirm the company’s previous data (AZURE trial analyses) on its proprietary MAF
Test® published in Lancet Oncology in 2018.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...